Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b cli… Read more
Oculis Holding AG Ordinary shares (OCS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.103x
Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) has a cash flow conversion efficiency ratio of -0.103x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.42 Million) by net assets ($130.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oculis Holding AG Ordinary shares - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Oculis Holding AG Ordinary shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oculis Holding AG Ordinary shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oculis Holding AG Ordinary shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aotecar New Energy Technology Co Ltd
SHE:002239
|
0.085x |
|
DL E&C Co Ltd
KO:375500
|
0.015x |
|
Donnelley Financial Solutions Inc
NYSE:DFIN
|
0.176x |
|
LIBERTY LAT.AMER.C DL-01
F:1LLC
|
N/A |
|
Inner Mongolia Lantai Industrial Co Ltd
SHG:600328
|
-0.009x |
|
Peoples Bancorp Inc
NASDAQ:PEBO
|
0.040x |
|
TECNOGLASS INC. DL-0001
F:7FH
|
N/A |
|
Coca-Cola Içecek Anonim Sirketi
PINK:COLZF
|
0.203x |
Annual Cash Flow Conversion Efficiency for Oculis Holding AG Ordinary shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of Oculis Holding AG Ordinary shares from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $73.38 Million | $-47.50 Million | -0.647x | -12.67% |
| 2023-12-31 | $93.73 Million | $-53.84 Million | -0.574x | -324.51% |
| 2022-12-31 | $-97.99 Million | $-25.07 Million | 0.256x | +12.82% |
| 2021-12-31 | $-60.95 Million | $-13.82 Million | 0.227x | -17.69% |
| 2020-12-31 | $-43.65 Million | $-12.03 Million | 0.276x | -- |